Article info
Research Article
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- ↵a 9804422000 Asim.Amin{at}carolinashealthcare.org
- ↵b elizabeth.plimack{at}fccc.edu
- ↵c marc.ernstoff{at}RoswellPark.org
- ↵d lionel.d.lewis{at}dartmouth.edu
- ↵e tbauer{at}tnonc.com
- ↵f dmcdermo{at}bidmc.harvard.edu
- ↵g carducci{at}jhmi.edu
- ↵h ckollmannsberger{at}bccancer.bc.ca
- ↵i rinib2{at}ccf.org
- ↵j daniel.heng{at}albertahealthservices.ca
- ↵k jennifer.knox{at}uhn.on.ca
- ↵l vossm{at}mskcc.org
- ↵m jennifer.spratlin{at}albertahealthservices.ca
- ↵n elmer.berghorn{at}bms.com
- ↵o lingfengy{at}gmail.com
- ↵p Hans.Hammers{at}UTSouthWestern.edu
Citation
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Publication history
- Received July 5, 2018
- Accepted September 26, 2018
- First published October 22, 2018.
Online issue publication
October 22, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.